Boston Scientific Co. (NYSE:BSX) Shares Bought by Mark Sheptoff Financial Planning LLC

Mark Sheptoff Financial Planning LLC grew its holdings in Boston Scientific Co. (NYSE:BSX) by 892.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 526 shares of the medical equipment provider’s stock after acquiring an additional 473 shares during the quarter. Mark Sheptoff Financial Planning LLC’s holdings in Boston Scientific were worth $41,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Eagle Bay Advisors LLC boosted its stake in Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 309 shares in the last quarter. First Foundation Advisors purchased a new position in shares of Boston Scientific in the first quarter worth $25,000. Triad Wealth Partners LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $26,000. Andra AP fonden purchased a new stake in shares of Boston Scientific during the second quarter valued at $29,000. Finally, RiverPark Advisors LLC acquired a new position in shares of Boston Scientific in the 1st quarter valued at $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the transaction, the executive vice president now owns 40,188 shares in the company, valued at $2,978,734.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 20,949 shares of company stock worth $1,627,877. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.1 %

Shares of NYSE:BSX opened at $82.57 on Thursday. The business’s 50 day moving average price is $78.46 and its 200-day moving average price is $74.45. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $84.11. The firm has a market capitalization of $121.14 billion, a price-to-earnings ratio of 69.39, a price-to-earnings-growth ratio of 2.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.04. The business had revenue of $4.12 billion for the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The company’s revenue was up 14.5% compared to the same quarter last year. During the same period last year, the firm posted $0.53 earnings per share. On average, equities research analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Deutsche Bank Aktiengesellschaft lifted their price target on Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a research report on Thursday, July 25th. BTIG Research lifted their target price on Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Barclays upped their target price on Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. Evercore ISI raised their price target on shares of Boston Scientific from $78.00 to $81.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 2nd. Finally, Morgan Stanley upped their price objective on shares of Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, July 15th. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $85.38.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.